100 Years of 'Innovation in Biology'

HUNGARY - Ceva Santé Animale is celebrating 100 years since the creation of the Phylaxia Serum Producing Company in Budapest.
calendar icon 11 October 2012
clock icon 2 minute read

Ceva Phylaxia is today a thriving biotech campus, which combines research, development, production of vaccines and commercial operations on one site. When in 1991, Ceva established its first campus for biological expertise in Budapest, the aim was to continue the tradition of veterinary biology started in 1912 with the formation of "Phylaxia" by Janos Koves.

Inspired by such famous researchers as Aladár Aujeszky, József Marek, Domokos Derzsy and Adorján Bartha, names that are familiar to veterinarians worldwide, Ceva Phylaxia's scientists are continuing a long history of Hungarian veterinary excellence.

Today, Ceva Phylaxia is at the centre of a rich collaborative network including many European and international partners, as well as Ceva's other biological campuses including Ceva Biomune, USA, and the group's bio-molecular vaccine research team in Yokohama, Japan among others.

Following the major success of its innovative, immune complex Gumboro vaccine - Transmune® IBD, Ceva researchers have demonstrated a complete compatibility with that of their latest Newcastle vector vaccine - Vectormune® ND making vaccination in the hatchery against these widely spread global diseases much simpler.

As a result, Ceva has named this dual vaccination: the 'Perfect Pair' - another step towards helping its customers in the enormous task of improving production and feeding a future population of nine billion.

Sarah Mikesell


Sarah Mikesell grew up on a five-generation family farming operation in Ohio, USA, where her family still farms. She feels extraordinarily lucky to get to do what she loves - write about livestock and crop agriculture. You can find her on Twitter or LinkedIn.

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.